Subscribe To

Price Alert Latest News Economic Calendar News

ORTIF / Ortho Regenerative Technologies earns repeat 'Outperform' rating, premium price target from Noble Capital

Noble Capital has repeated an 'Outperform' rating and C$1.35 (US$1.05) price target again tagged Ortho Regenerative Technologies Inc (CSE:ORTH) following news the first patient in the ORTHO-R rotator cuff Phase I/II trial has received surgical treatment. Ortho said recently that it had begun enrolling patients in its US phase I/II clinical trial of rotator cuff tear repair after the first patient surgery was completed in its US phase I/II clinical trial of rotator cuff tear repair. Read More

Demo Live Account See Partner Details

Content Topics

Ortho

Regenerative

Technologies

Earns

Repeat

Outperform

outperform

Rating

Premium

Target

Capital

Stock

ORTIF

Posted: Jul 28 2022, 10:17

Author Name: Proactive Investors

ORTIF News

By Proactive Investors
September 7, 2022

Ortho Regenerative Technologies announces name change to ChitogenX

Ortho Regenerative Technologies Inc (CSE:ORTH) announced that it has changed its corporate name to ChitogenX Inc to better reflect the company's expan

By Proactive Investors
July 28, 2022

Ortho Regenerative Technologies earns repeat 'Outperform' rating, premium price target from Noble Capital

Noble Capital has repeated an 'Outperform' rating and C$1.35 (US$1.05) price target again tagged Ortho Regenerative Technologies Inc (CSE:ORTH) foll

By Proactive Investors
July 27, 2022

Ortho Regenerative Technologies initiates patient enrollment following completion of first patient surgery in US phase I/II rotator cuff tear repair clinical trial

Ortho Regenerative Technologies Inc (CSE:ORTH) announced that it has begun the enrollment of patients after the first patient surgery was completed i

By Proactive Investors
June 24, 2022

Ortho Regenerative Technologies highlights milestones achieved in 1Q ended April 30, 2022

Ortho Regenerative Technologies Inc (CSE:ORTH) has reported its financial results and highlights for the first quarter ended April 30, 2022. Among the

By Proactive Investors
June 3, 2022

Ortho Regenerative Technologies is at the forefront of regenerative medicine with its elegantly simple tissue repair technology

Ortho Regenerative Technologies Inc (CSE:ORTH) is developing novel tissue repair therapies with the goal of dramatically increasing the success rates

By Proactive Investors
May 26, 2022

Ortho Regenerative Technologies awarded $500,000 grant to advance the development of its ORTHO-M platform for meniscus repair

Ortho Regenerative Technologies Inc (CSE:ORTH) announced that it has received a $500,000 grant to advance the development of its secondary technology

By Proactive Investors
May 4, 2022

Ortho Regenerative Technologies secures US patent for its ORTHO-R soft tissue repair platform

Ortho Regenerative Technologies (CSE:ORTH) Inc said the United States Patent and Trademark Office (USPTO) has issued a patent related to the company'

By Proactive Investors
April 6, 2022

Ortho Regenerative Technologies closes oversubscribed non-brokered private placement for $3.2M

Ortho Regenerative Technologies (CSE:ORTH) Inc told investors it closed an oversubscribed non-brokered private placement of units for gross proceeds o

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.